Viable mouse models of acid beta-glucosidase deficiency: the defect in Gaucher disease
- PMID: 14578207
- PMCID: PMC1892407
- DOI: 10.1016/s0002-9440(10)63566-3
Viable mouse models of acid beta-glucosidase deficiency: the defect in Gaucher disease
Abstract
Gaucher disease is an autosomal recessively inherited disease caused by mutations at the acid beta-glucosidase (GCase) locus (GBA). To develop viable models of Gaucher disease, point mutations (pmuts), encoding N370S, V394L, D409H, or D409V were introduced into the mouse GCase (gba) locus. DNA sequencing verified each unique pmut. Mutant GCase mRNAs were near wild-type (WT) levels. GCase activities were reduced to 2 to 25% of WT in liver, lung, spleen, and cultured fibroblasts from pmut/pmut or pmut/null mice. The corresponding brain GCase activities were approximately 25% of WT. N370S homozygosity was lethal in the neonatal period. For the other pmut mice, a few storage cells appeared in the spleen at > or =7 months (D409H or D409V homozygotes) or > or =1 year (V394L homozygotes). V394L/null, D409H/null, or D409V/null mice showed scattered storage cells in spleen at approximately 3 to 4 months. Occasional storage cells (sinusoidal cells) were present in liver. In D409V/null mice, large numbers of Mac-3-positive storage cells (ie, macrophages) accumulated in the lung. Glycosphingolipid analyses showed varying rates of progressive glucosylceramide accumulation in visceral organs of pmut/pmut or pmut/null mice, but not in brain. These GCase-deficient mice provide tools for gaining insight into the pathophysiology of Gaucher disease and developing improved therapies.
Figures
) site and the individual exon 9 mutations (*).
Similar articles
-
Gaucher disease mouse models: point mutations at the acid beta-glucosidase locus combined with low-level prosaposin expression lead to disease variants.J Lipid Res. 2005 Oct;46(10):2102-13. doi: 10.1194/jlr.M500202-JLR200. Epub 2005 Aug 1. J Lipid Res. 2005. PMID: 16061944
-
In vivo and ex vivo evaluation of L-type calcium channel blockers on acid beta-glucosidase in Gaucher disease mouse models.PLoS One. 2009 Oct 7;4(10):e7320. doi: 10.1371/journal.pone.0007320. PLoS One. 2009. PMID: 19809509 Free PMC article.
-
Ex vivo and in vivo effects of isofagomine on acid β-glucosidase variants and substrate levels in Gaucher disease.J Biol Chem. 2012 Feb 3;287(6):4275-87. doi: 10.1074/jbc.M111.280016. Epub 2011 Dec 13. J Biol Chem. 2012. PMID: 22167193 Free PMC article.
-
Gaucher disease among Chinese patients: review on genotype/phenotype correlation from 29 patients and identification of novel and rare alleles.Blood Cells Mol Dis. 2007 May-Jun;38(3):287-93. doi: 10.1016/j.bcmd.2006.11.003. Epub 2006 Dec 29. Blood Cells Mol Dis. 2007. PMID: 17196853 Review.
-
Gaucher disease paradigm: from ERAD to comorbidity.Hum Mutat. 2012 Oct;33(10):1398-407. doi: 10.1002/humu.22124. Epub 2012 Jun 11. Hum Mutat. 2012. PMID: 22623374 Review.
Cited by
-
A Comparative Biochemical and Pathological Evaluation of Brain Samples from Knock-In Murine Models of Gaucher Disease.Int J Mol Sci. 2024 Feb 2;25(3):1827. doi: 10.3390/ijms25031827. Int J Mol Sci. 2024. PMID: 38339105 Free PMC article.
-
Animal Models for the Study of Gaucher Disease.Int J Mol Sci. 2023 Nov 7;24(22):16035. doi: 10.3390/ijms242216035. Int J Mol Sci. 2023. PMID: 38003227 Free PMC article. Review.
-
α-Synuclein expression in response to bacterial ligands and metabolites in gut enteroendocrine cells: an in vitro proof of concept study.Brain Commun. 2023 Oct 24;5(6):fcad285. doi: 10.1093/braincomms/fcad285. eCollection 2023. Brain Commun. 2023. PMID: 37953845 Free PMC article.
-
Exploring Pro-Inflammatory Immunological Mediators: Unraveling the Mechanisms of Neuroinflammation in Lysosomal Storage Diseases.Biomedicines. 2023 Apr 1;11(4):1067. doi: 10.3390/biomedicines11041067. Biomedicines. 2023. PMID: 37189685 Free PMC article. Review.
-
Mechanisms of Glucocerebrosidase Dysfunction in Parkinson's Disease.J Mol Biol. 2023 Jun 15;435(12):168023. doi: 10.1016/j.jmb.2023.168023. Epub 2023 Feb 23. J Mol Biol. 2023. PMID: 36828270 Review.
References
-
- Beutler E, Grabowski GA: Gaucher disease. Scriver CR Beaudet AL Sly WS Valle D eds. The Metabolic and Molecular Bases of Inherited Diseases. 2001:pp 3635-3668 McGraw-Hill New York
-
- Blom S, Erikson A: Gaucher disease–Norrbottnian type: neurodevelopmental, neurological, and neurophysiological aspects. Eur J Pediatr 1983, 140:316-322 - PubMed
-
- Kolodny EH, Ullman MD, Mankin HJ, Raghavan SS, Topol J, Sullivan JL: Phenotypic manifestations of Gaucher disease: clinical features in 48 biochemically verified type 1 patients and comment on type 2 patients. Prog Clin Biol Res 1982, 95:33-65 - PubMed
-
- Volk BW, Wallace BJ, Adachi M: Infantile Gaucher’s disease: electron microscopic and histochemical studies of a cerebral biopsy. J Neuropathol Exp Neurol 1967, 26:176-177 - PubMed
-
- Adachi M, Wallace BJ, Schneck L, Volk BW: Fine structure of central nervous system in early infantile Gaucher’s disease. Arch Pathol (Chicago) 1967, 83:513-526 - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
